STATUS DECISION OF CONTROLLED 
AND NON-CONTROLLED SUBSTANCE(S)

Substance:  2-Benzylamino-1-(3,4-methylenedioxyphenyl)butan-1-one (BMDP)

Based on the current information available to the Office of Controlled Substances, it appears that the above substance is:

Controlled  ✔
Not Controlled  ❌

under the schedules of the *Controlled Drugs and Substances Act* (CDSA) for the following reason(s):

- 2-Benzylamino-1-(3,4-methylenedioxyphenyl)butan-1-one (BMDP) is an amphetamine analogue and therefore is included under item 1 of Schedule III to the CDSA.

Prepared by: ___________________________________________  Date: November 30th 2011
Evelyn C Soo

Verified by: ___________________________________________  Date: __________
Mark Kozlowski

Approved by: ___________________________________________  Date: __________
DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES

This status was requested by: CBSA, Julie Delahunt
Drug Status Report

**Drug:** 2-Benzylamino-1-(3,4-methylenedioxyphenyl)butan-1-one (BMDP)

**Drug Name Status:** 2-Benzylamino-1-(3,4-methylenedioxyphenyl)butan-1-one is the common name.

**Chemical Name:** 1-(1,3-benzodioxol-5-yl)-2-(benzylamino)butan-1-one

**Chemical structure:**

![Chemical structure images](image)

**Molecular Formula:** $C_{18}H_{19}NO_3$

**Pharmacological class / Application:** Stimulant

**CAS-RN:** Unknown

**International status:**

US: 2-Benzylamino-1-(3,4-methylenedioxyphenyl)butan-1-one (BMDP) is not listed in the *US Controlled Substances Act* and is not mentioned anywhere on the DEA website.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control, the Green List - List of Psychotropic Substances under International Control, nor the Red List - List of Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances Under International Control.

Canadian Status: 2-Benzylamino-1-(3,4-methylenedioxyphenyl)butan-1-one (BMDP) is not listed specifically in the schedules to the CDSA. The substance is a designer stimulant drug related to the more common designer drug butylone (2-(methylamino)-1-(3,4-methylenedioxyphenyl)butan-1-one) which was previously reviewed and considered included under item 1 of Schedule III to the CDSA as an amphetamine analogue. Currently, benzphetamine is listed as sub-item 1(18) in Schedule III to the CDSA and is considered similar to BMDP in that the amine groups of both compounds are substituted with a phenyl ring. As shown above, BMDP also is substantially similar in structure to MDMA which is sub-item 1(9) of Schedule III to the CDSA. Given the substantial similarities of the substance to the amphetamines, it must be included under item 1 of Schedule III to the CDSA. It is noteworthy
that BMDP is a new drug that was reported to the EMCDDA and Europol in December 2010.

**Recommendation:** 2-Benzylamino-1-(3,4-methylenedioxyphenyl)butan-1-one (BMDP) is included under item 1 of Schedule III to the CDSA and is a controlled substance.

**Date:** November 30th, 2011